Business Context and Reporting Period
Company: Ocular Therapeutix, Inc. (OCUL)
Filing Type: Form 8-K (Current Report)
Report Date: August 3, 2026
Reporting Period: Quarter ended June 30, 2026
Item Reported: Item 2.02 Results of Operations and Financial Condition
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for the quarter ended June 30, 2026. The text does not provide specific numerical values for the following metrics:
- Revenue
- Net Profit/Loss
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not contain data regarding material changes versus the prior comparable period. Specific operational or financial variances are detailed in the referenced press release (Exhibit 99.1), which is not included in the input text.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the announcement of financial results but does not include specific management commentary, forward-looking guidance, or outlook statements within the text provided.
Risks and Contingencies: No specific risks, contingencies, or unusual items are described in the cover document text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 3, 2026) for actual revenue, net loss, and cash position figures.
- Verify year-over-year and quarter-over-quarter performance trends not present in this summary.
- Check for updated clinical trial milestones or regulatory approvals mentioned in the full press release.
- Confirm cash runway and burn rate details from the full financial disclosure.